Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis

Chiara Citterio; Michela Baccini; Elena Orlandi; Camilla Di Nunzio; Luigi Cavanna

doi:10.18632/oncotarget.25639

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis

Chiara Citterio, Michela Baccini, Elena Orlandi, Camilla Di Nunzio and Luigi Cavanna _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:29801-29809. https://doi.org/10.18632/oncotarget.25639

Metrics: PDF 2221 views | HTML 4567 views | ?

Abstract

Chiara Citterio1, Michela Baccini2, Elena Orlandi1, Camilla Di Nunzio1 and Luigi Cavanna1

1Onco-Haematology Department, Hospital Guglielmo da Saliceto, 29121 Piacenza, Italy

2Department of Statistics, Informatics, Applications “G. Parenti”, Università di Firenze, 50134 Florence, Italy

Correspondence to:

Luigi Cavanna, email: [email protected]

Keywords: pancreatic cancer; second-line chemotherapy; oxaliplatin; irinotecan; gemcitabine based chemotherapy

Received: April 24, 2018 Accepted: June 04, 2018 Published: July 03, 2018

ABSTRACT

Guidelines for treatment of metastatic pancreatic cancer recommend a second line based on Fluoropyrimidine (FP) alone or in combination with Oxaliplatin (OXA) or Irinotecan (IRI) after a first line treatment based on Gemcitabine (GEM). We conducted a Bayesian network meta-analysis to compare currently available therapies to treat metastatic pancreatic cancer in the second line, considering as efficacy measures overall survival (OS) and progression free survival (PFS). Published randomized trials were identified using electronic databases (MEDLINE, PubMed, https://clinicaltrials.gov/ and American Society of clinical oncology). 8 studies met the inclusion criteria for a total of 1,587 patients and 7 different therapeutic schemes. The results suggested that the use of IRI-FP-Folinic Acid scheme in the second-line treatment of metastatic pancreatic cancer may offer a benefit in terms of OS and PFS for patients not previously treated with these drugs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25639

Publication Alerts

Post-Publication Promotion

Publication Discount

Meta-Analysis:

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis

Abstract